Home > Journals > Minerva Cardioangiologica > Past Issues > Articles online first > Minerva Cardioangiologica 2020 Jul 08

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Cardioangiologica 2020 Jul 08

DOI: 10.23736/S0026-4725.20.05202-0

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Can the expression of the metalloproteinase 9 gene and its inhibitor be considered as markers of heart failure?

Joanna GŁOGOWSKA-LIGUS 1 , Józefa DĄBEK 2, Mieczysław PIECHOTA 3, Weronika GALLERT-KOPYTO 4, Tomasz LEPICH 5, Dariusz KORZEŃ 6, Zbigniew GĄSIOR 2

1 Department of Epidemiology, Faculty of Health Sciences in Bytom, Medical University of Silesia, Katowice, Poland; 2 Department of Cardiology, Faculty of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland; 3 Department of Cardiology, City Hospital, Tychy, Poland; 4 Rehabilitation Workshop Weronika Gallert-Kopyto, Katowice, Poland; 5 Department of Human Anatomy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland; 6 Department of Anesthesiology and Intensive Care with Cardiac Monitoring, Independent Public Clinical Hospital No.7, Upper Silesian Medical Center, Medical University of Silesia in Katowice, Katowice, Poland in Katowice, Poland


PDF


BACKGROUND: Heart failure (HF) is a major cause of mortality in developed countries. Its formation is associated with a change in the transcriptional activity of many genes. The aim of the study was to select, from the group of genes related to coronary atherosclerosis and heart failure, genes differentiating patients with coronary heart disease and heart failure on the basis of myocardial ischemia from healthy people, and then genes differentiating patients with
various stages of heart failure.
METHODS: The study was carried out using the oligonucleotide microarray technique HGU133A (Affymetrix). Cluster analysis showed a homogeneous division of the study group into patients with heart failure and healthy patients with excluded coronary artery disease and patients with heart failure depending on the size of the left ventricle ejection fraction.
RESULTS: The study showed that genes differentiating the group of patients from healthy people were: TGF-β1, TIMP-1 and - MMP -9. The analysis also showed that genes differentiated patients with advanced heart failure in the course of coronary disease and ejection fraction (LVEF) 20% and patients from the group with 40% LVEF were MMP-9 and TIMP-1.
CONCLUSIONS: Extracting from the group of genes related to coronary atherosclerosis and cardiac failure: MMP-9, TGF-β1 and TIMP-1 differentiating patients with heart failure on the basis of myocardial ischemia in varying degrees of severity from healthy people may indicate their significant contribution to disease development. Also increased expression of the metalloproteinase gene 9 (MMP-9) with a simultaneous decrease in the expression of its tissue inhibitor 1 (TIMP-1) in the studied group of patients with ischemic heart failure differing in left ventricular ejection fraction (LVEF) makes them the markers of progression in failure.


KEY WORDS: Heart failure; Oligonucleotide microarray; Metallopoteinases

top of page